Anavex Life Sciences Corp (AVXL)

[Bourbon_on_my_cornflakes]

MAXIM: From Autism and Alzheimer's to Parkinson's, data keeps emerging
suggesting 2-73 is an active compound. Additional data for 2-73 in a
model for experimental parkinsonism was presented. The poster titled,
“ANAVEX2-73, a clinical Alzheimer drug candidate, induces neurorestoration
in experimental parkinsonism.” Investigators said: “These new results
indicate that ANAVEX2-73 has robust neurorestorative effects on the
nigrostriatal dopaminergic pathway in all doses tested. The encouraging
results we have gathered in this model, coupled with the favorable profile
of this compound in the Alzheimer’s disease trial, support the notion that
ANAVEX2-73 is a promising clinical candidate drug for Parkinson’s disease.”
• It was previously shown that ANAVEX2-73 significantly promotes recovery
of motor functions (p<0.05), induces higher levels of striatal dopamine fibers
(p<0.05) and reduces microglial activation (p<0.05) in a mouse model of
nigrostriatal dopaminergic degeneration relevant to Parkinson's disease. The
additional data reveals that ANAVEX2-73 not only seems to have a wide doseresponse
profile but also activates neuroplasticity mechanisms and exerts
noticeable neurorestorative effects on striatal dopamine axon fibers.